Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.44 |
| ▸ | CTSK | P43235 | 3/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | GHSR | Q92847 | 4/20 | 0.38 |
| ▸ | MC3R | P41968 | 7/20 | 0.36 |
| ▸ | MC4R | P32245 | 6/20 | 0.36 |
| ▸ | MC1R | Q01726 | 6/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | FCER2 | P06734 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6323483 | 1.00 | CTSS (0.44) | CTSSCTSKCTSBGHSRMC3R | |
| SCHEMBL6319767 | 0.92 | PTPN1 (0.42) | CTSSCTSKCTSBGHSRPTPN1 | |
| SCHEMBL6319778 | 0.92 | PTPN1 (0.42) | CTSSCTSKCTSBGHSRPTPN1 | |
| SCHEMBL6317984 | 0.86 | CTSS (0.52) | CTSSCTSKCTSBMC3RMC4R | |
| SCHEMBL6319720 | 0.79 | GHSR (0.56) | CTSSCTSKCTSBGHSRMC3R | |
| SCHEMBL6320792 | 0.79 | CTSS (0.41) | CTSSCTSKCTSBGHSRMC3R | |
| SCHEMBL7061721 | 0.77 | CCR1 (0.46) | CTSSCTSKCTSBMC3RMC4R | |
| SCHEMBL7063297 | 0.75 | MC3R (0.39) | CTSSCTSKCTSBMC3RMC4R | |
| SCHEMBL6320865 | 0.74 | CTSS (0.40) | CTSSCTSKCTSBGHSR | |
| SCHEMBL6324455 | 0.74 | CTSS (0.39) | CTSSCTSKCTSBGHSRMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6939880-B2 | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 2005-09-06 | — | — | US | disclosed |
| US-6555570-B2 | Growth hormone secretagogous with improved bioavailability | NOVO NORDISK A/S (DE) | 2003-04-29 | — | — | US | disclosed |
| US-20030055261-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-03-20 | — | — | US | disclosed |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | HELSINN THERAPEUTICS (U.S.), INC. | 2003-02-27 | — | — | US | disclosed |
| US-6127391-A | A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY | NOVO NORDISK A/S (DK) | 2000-10-03 | — | — | US | disclosed |
| US-5977178-A | Compounds with growth hormone releasing properties | NOVO NORDISK A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| EP-0907374-A1 | GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS | NOVO NORDISK A/S (DK) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997046252-A1 | GROWTH HORMONE COMPONENT AND BONE ANTI-RESORPTIVE AGENT IN CYCLIC (COHERENCE) TREATMENT OF OSTEOPOROSIS | NOVO NORDISK A/S (DK) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055261-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, IGFBP1 | CTSS 2319/4885CTSK 1324/4885CTSB 967/4885 |
| US-20030040483-A1 | Compounds with growth hormone releasing properties | GHRHR, GHSR, GRPR | CTSS 2636/4885CTSK 1778/4885CTSB 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.